Horizon Discovery – Parkwalk UCEF I exit
We are delighted to have generated a 2.36x return (3.37x inclusive of initial tax reliefs) for our investors on the sale of the University of Cambridge Enterprise Fund I holding in Horizon Discovery plc. The investment was held for… Read More
Predictimmune – Parkwalk closes investment
We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Fund IV have completed an investment in Predictimmune Limited, a spinout company from the University of Cambridge.
Parkwalk closes PhoreMost follow-on investment
We are pleased to announce that Parkwalk has made an investment in Phoremost, a Cambridge University spinout, as part of a Series ‘B’ round of equity funding, alongside Amadeus Capital Partners and the University. Phoremost’s mission is to accelerate,… Read More
Congenica – Parkwalk closes investment
We are delighted to announce that the Parkwalk Opportunities Fund and the Parkwalk Technology Fund VII have invested in a $10m Series ‘B’ financing round for Congenica Limited, which spun out of the Wellcome Trust Sanger Institute and Department… Read More
Horizon Discovery – Strong Revenue Growth and Focus on Operational Gearing Underpin Path to Profitability
Cambridge, UK, 20 September 2016: Horizon Discovery Group plc (LSE: HZD), a world leader in the application of gene editing technologies, announces its interim results for the six months ended 30 June 2016. Highlights (including post period end):… Read More
Parkwalk closes Xerion investment
We are pleased to announce that the University of Oxford Isis Fund II has made an investment in Xerion, a nanoparticle company spun-out of the University with a novel treatment for cancer. Xerion seeks to commercialise Dr Helen Townley’s… Read More
Parkwalk closes Quethera investment
We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in Quethera, a gene therapy company spun-out of the University with a novel treatment for glaucoma. Quethera announces seed financing to develop… Read More
Horizon Discovery – Placing to raise approximately £25 million to accelerate the Company’s growth strategy
Horizon Discovery Group plc (LSE:HZD), the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, is pleased to announce a conditional non-pre-emptive placing of 13,157,895 New Placing Shares… Read More
Parkwalk closes PhoreMost investment
We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in PhoreMost as part of a £4m series ‘A’ round of equity and grant funding, of which the equity tranche was… Read More
Horizon Discovery – Positive Trading Update
Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering Cambridge, UK – 19th January 2014: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the… Read More
Horizon Discovery – acquires Sage Labs Inc. for $48M
Acquisition makes Horizon the world’s leading gene-editing and translational genomics company Highlights · Horizon acquires Sage Labs Inc. for up to $48M (£29M) comprising up to $16M in cash and up to $32M in new ordinary shares · Acquisition creates a… Read More
Horizon Discovery – Interim Results
Interim Results in-line and Panmure reaffirms ‘Buy Rating’: Interim Results for the Six Months Ended 30 June 2014 Horizon Reports a Strong First Half Positioning the Company for Continued Growth Cambridge, UK, 23 September 2014: Horizon Discovery Group… Read More
Horizon Discovery – wins European Mediscience’s Emerging Star Award 2014
Horizon Discovery Group plc, the international life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, is delighted to announce that it has won the “Emerging Star” category at last… Read More
Horizon Discovery Says It Has Continued To Trade Strongly Since IPO
Horizon Discovery Group PLC said Wednesday that it had continued to trade strongly since its initial public offering. The company said it had traded “at least in line with expectations”, and that it is pursuing its strategy to… Read More
Horizon Discovery – Record AIM $113m IPO
Parkwalk portfolio company Horizon Discovery is set to create UK stock market history with a significantly oversubscribed AIM IPO on Thursday March 27, with a market cap of £120.5 million after raising £68.6m from institutional investors against an original target… Read More
Horizon – Intention to float on AIM
Horizon Discovery Group plc Announces Intention to Float THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED… Read More
Horizon Discovery
Appointment of Chairman – Horizon Discovery has appointed Dr. Ian Gilham as Chairman of its Board of Directors. Dr. Gilham’s healthcare industry career spans thirty years encompassing all aspects of successful company growth and development. He was Chief Executive… Read More
Horizon Discovery
Horizon Discovery Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines Cambridge, UK, 30 January 2014: Horizon Discovery™ (Horizon), a leading provider of research… Read More
Horizon Discovery
Jan 7 (Reuters) – Horizon Discovery: * Horizon discovery and Astrazeneca have entered into a research, collaboration and license agreement * Agreement to explore a range of oncology-relevant genotypes * Will receive an undisclosed upfront payment * Eligible… Read More
Horizon Discovery
Horizon Discovery named in the Deloitte Tech Fast 50 2013
